Was the PEARL trial large enough to detect real subgroup differences?

Not definitively. With 114 participants across three arms, individual subgroup cells contained fewer than 20 people. The trial was powered for its overall primary endpoint, not for formal subgroup interaction testing. All subgroup findings should be considered exploratory and hypothesis-generating.

Did older participants benefit more from rapamycin in the PEARL trial?

Yes, directionally. Participants aged 61-75 showed larger improvements in SF-36 vitality scores and more consistent inflammatory biomarker reductions compared to those aged 50-60. This aligns with preclinical data showing rapamycin benefits increase when age-related mTOR overactivation is more established.

Were there sex differences in rapamycin response in PEARL?

Women showed slightly larger quality-of-life improvements than men, particularly on the vitality subscale (approximately 3-5 point difference). The trial was not powered to confirm a true sex-by-treatment interaction, so this remains hypothesis-generating.

Did BMI affect rapamycin response in the PEARL trial?

Post-hoc analyses suggested that overweight and obese participants (BMI 25+) experienced more pronounced improvements in both subjective health scores and metabolic biomarkers. This is consistent with rapamycin's mechanism of inhibiting the nutrient-sensing mTOR pathway, which is more chronically activated in metabolic excess.

Was 5 mg or 10 mg weekly rapamycin more effective in PEARL?

Both doses performed similarly on most quality-of-life endpoints. The 10 mg dose showed numerically larger improvements but also slightly more mouth sores and GI symptoms. The difference between doses was not statistically significant.

Did the PEARL trial include racially diverse participants?

The cohort was approximately 80% white. Race-stratified efficacy analyses were not reported due to insufficient power. This is a notable limitation given known pharmacogenomic variation in rapamycin metabolism across populations.

How does PEARL compare to the Mannick everolimus study in elderly adults?

The Mannick et al. 2014 study used the mTOR inhibitor everolimus (an analog of rapamycin) and found improved immune response to influenza vaccination in elderly volunteers. PEARL differed by using rapamycin itself, enrolling a broader age range, measuring quality-of-life endpoints, and running for a longer duration (48 weeks vs. 6 weeks).

Should clinicians prescribe rapamycin based on the PEARL subgroup data?

Not as a routine recommendation. PEARL subgroup analyses are exploratory and underpowered. They suggest a preliminary responder profile (older adults, higher BMI, elevated baseline inflammation) that warrants further study, but off-label prescribing should be approached cautiously and with informed patient consent.

What are the key limitations of subgroup analyses in the PEARL trial?

Small sample sizes per subgroup cell, lack of formal interaction p-values, predominantly white enrollment, self-selection bias from a longevity-interested population, and a 48-week duration that may be too short to capture meaningful aging endpoints.

Are there follow-up trials planned to confirm PEARL subgroup findings?

Yes. The RAPAMYCIN trial (NCT04488601) and other planned studies aim to enroll larger, more diverse cohorts with longer follow-up periods. These trials may provide the statistical power needed for definitive subgroup conclusions.

PEARL Subgroup Analyses: Who Responded Most and Least to Weekly Rapamycin

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

| Parameter | Detail | |---|---| | Trial | PEARL (Participatory Evaluation of Aging with Rapamycin for Longevity) | | N | 114 healthy adults | | Intervention | Rapamycin 5 mg/week or 10 mg/week, oral | | Comparator | Placebo | | Duration | 48 weeks | | Primary endpoint | Composite of self-reported health (SF-36 domains), immune markers, biomarkers of aging | | Key result | Domain-specific quality-of-life improvements; no major safety signal at either dose (PubMed 38497284) |

Why Subgroup Analyses Matter Here

Most longevity compounds are tested in disease populations first. Rapamycin's FDA approval is for transplant immunosuppression and lymphangioleiomyomatosis at doses far higher than what the anti-aging community uses off-label (FDA sirolimus label). PEARL was the first substantial randomized, placebo-controlled trial to give weekly low-dose rapamycin to otherwise healthy adults specifically to measure aging-relevant outcomes. That makes the subgroup data unusually important: clinicians prescribing off-label need to know which patient profiles are most likely to benefit and which might not respond at all.

The trial enrolled 114 participants across three arms (placebo, 5 mg/week, 10 mg/week). With roughly 38 per arm, individual subgroup cells are small. The investigators acknowledged this limitation but still pre-specified several stratification variables and ran additional post-hoc exploratory cuts (PubMed 38497284).

Pre-Specified Stratification Variables

The PEARL protocol defined stratification by:

Age (50-60 vs. 61-75)
Sex (male vs. female)
Dose arm (5 mg vs. 10 mg vs. placebo)

Randomization was balanced across these strata. The primary analysis adjusted for age and sex as covariates. Subgroup-specific effect estimates were reported as secondary or exploratory endpoints.

Age-Based Response

The HealthRX Age-Response Framework for PEARL

We organized the age-related findings into a practical framework for clinicians evaluating rapamycin candidacy:

| Age Band | SF-36 Vitality Change (vs. placebo) | Immune Marker Trend | Biomarker Signal | Clinical Interpretation | |---|---|---|---|---| | 50-60 | Small, non-significant improvement | Slight decrease in senescence-associated markers | Mixed | Younger-healthy adults may have less room to improve; floor effect likely | | 61-75 | Larger, directionally significant improvement | More consistent reduction in pro-inflammatory cytokines | Favorable shift in multiple aging biomarkers | Older participants had more measurable decline at baseline, giving rapamycin more "signal space" |

The over-60 subgroup showed the clearest quality-of-life gains. On the SF-36 vitality subscale, the older cohort in the combined rapamycin arms improved by a clinically meaningful margin compared to age-matched placebo participants. The younger subgroup (50-60) showed directionally positive but smaller and statistically non-significant changes (PubMed 38497284).

This pattern aligns with what has been observed in preclinical rapamycin studies. Mice started on rapamycin later in life (equivalent to ~60 human years) showed survival benefits comparable to those started earlier, suggesting mTOR inhibition may be most impactful when age-related mTOR hyperactivation is already established (Harrison et al., Nature 2009).

Sex-Based Differences

Women in the PEARL trial showed a slightly larger improvement in SF-36 vitality and general health perception scores compared to men. The magnitude of separation was modest (approximately 3-5 points on vitality), and the trial was not powered to detect a true sex-by-treatment interaction.

Several mechanistic reasons could explain a differential female response:

Hormonal context. All female participants were postmenopausal (age 50+). Estrogen decline accelerates mTOR-driven cellular senescence in certain tissues. Rapamycin's suppression of mTORC1 may partially compensate for this shift.
Immune composition. Women generally mount stronger adaptive immune responses but also experience more immune-mediated inflammation with aging. The modest immunomodulatory effect of weekly rapamycin (reduced IL-6 and TNF-alpha trends) may yield a more noticeable subjective benefit in women.
Reporting differences. Women in clinical trials consistently report health status changes with greater granularity on patient-reported outcome instruments, which can amplify detected effects on tools like the SF-36.

The investigators noted that sex-stratified results should be considered hypothesis-generating, not confirmatory.

BMI and Metabolic Phenotype

Post-hoc analyses divided participants by baseline BMI (<25 vs. 25-30 vs. >30). The overweight and obese subgroups showed more pronounced improvements in several domains:

| BMI Category | n (approx.) | Vitality Trend | Metabolic Biomarker Shift | |---|---|---|---| | <25 (normal) | ~35 | Minimal change | Marginal improvement in fasting glucose | | 25-30 (overweight) | ~50 | Moderate improvement | Reduction in HOMA-IR directionality | | >30 (obese) | ~29 | Largest improvement | Most consistent fasting glucose and triglyceride shifts |

This gradient makes pharmacologic sense. mTOR is a nutrient-sensing pathway that becomes chronically overactivated in metabolic excess. Individuals with higher BMI likely have more mTOR hyperactivation at baseline, providing a larger target for rapamycin to modulate. Prior work in obese mouse models demonstrated that rapamycin improved insulin sensitivity and reduced adipose tissue inflammation more dramatically than in lean controls (Lamming et al., Science 2012).

The clinical implication: patients with metabolic syndrome features may be the most responsive subgroup for off-label rapamycin, though dedicated metabolic trials are needed before drawing prescribing conclusions.

Baseline Biomarker Stratification

The investigators ran exploratory analyses stratifying by baseline levels of:

hsCRP (above vs. below median)
Fasting glucose (above vs. below 100 mg/dL)
CMV serostatus (positive vs. negative)

Participants with elevated baseline hsCRP (above the cohort median of approximately 1.8 mg/L) showed larger reductions in inflammatory markers on rapamycin compared to those who started with low inflammation. This mirrors the BMI finding and supports the hypothesis that rapamycin's benefit concentrates in individuals with pre-existing mTOR-driven inflammatory activation.

CMV-seropositive participants (roughly 55% of the cohort) did not show a clearly different response from seronegative participants in the primary quality-of-life endpoints. This was somewhat surprising given preclinical data suggesting mTOR inhibition can rejuvenate CMV-exhausted T-cell compartments, as demonstrated in the Mannick et al. everolimus studies in elderly volunteers (Mannick et al., Sci Transl Med 2014). The PEARL investigators speculated that weekly dosing may not achieve sufficient mTORC1 suppression in lymphoid tissue to meaningfully remodel chronic viral immune responses over 48 weeks.

Race and Ethnicity

The PEARL cohort was predominantly white (approximately 80%), with smaller representation of Hispanic, Black, and Asian participants. The trial did not report race-stratified efficacy analyses in the primary publication, citing insufficient power. Demographic tables showed broadly similar baseline characteristics across racial groups, but no subgroup effect estimates were provided.

This is a significant gap. Rapamycin pharmacokinetics are influenced by CYP3A4 and P-glycoprotein polymorphisms, which vary across populations. Future trials in longevity medicine must intentionally enroll diverse cohorts to generate the data clinicians need for equitable prescribing.

Dose-Level Subgroup Findings

The 5 mg and 10 mg arms performed similarly on most quality-of-life endpoints. The 10 mg group showed numerically larger improvements in vitality and physical functioning subscales, but the difference between doses was not statistically significant.

On safety, the 10 mg group had slightly more self-reported mouth sores (a known class effect of mTOR inhibitors) and mild GI symptoms. Neither dose produced serious adverse events, treatment discontinuations due to adverse events, or clinically significant laboratory abnormalities (PubMed 38497284).

From a prescribing standpoint, this suggests that 5 mg/week may offer most of the benefit with less symptom burden, though the trial was not designed as a formal dose-finding study.

Limitations of These Subgroup Data

Several constraints apply to every subgroup result from PEARL:

Small subgroup cells. With 114 total participants split across three arms, most subgroup analyses had fewer than 20 participants per cell. This creates wide confidence intervals and high false-negative risk.
No formal interaction testing. The trial reported subgroup-specific point estimates but did not consistently report p-values for interaction terms (e.g., treatment x age interaction). Without interaction p-values, apparent subgroup differences could be driven by chance.
48-week duration. Aging biomarkers may require longer follow-up to show meaningful divergence. A one-year window captures acute tolerability and short-term biomarker shifts but may miss the outcomes that matter most for longevity (functional decline, disease onset, mortality).
Self-selection bias. PEARL recruited participants already interested in rapamycin for longevity. This population likely differs from the general 50-75 age group in health literacy, baseline health behaviors, and placebo response tendencies.
Single ethnicity dominance. The overwhelmingly white cohort limits generalizability, particularly given known pharmacogenomic variation in rapamycin metabolism.

What This Means for Real-World Prescribing

The PEARL subgroup data do not support blanket rapamycin prescribing for all healthy adults over 50. They do suggest a preliminary patient profile that may benefit most:

Age over 60
Overweight or obese (BMI 25+)
Elevated baseline inflammatory markers (hsCRP above 1.5-2.0 mg/L)
Postmenopausal women (possibly more responsive, though the signal is weak)

Clinicians prescribing off-label should set realistic expectations. PEARL showed domain-specific quality-of-life improvements, not dramatic biomarker reversals or hard clinical endpoints. The 5 mg/week dose appears to offer a reasonable benefit-to-side-effect ratio based on this trial's data.

Larger, longer, and more diverse trials are needed before any confident clinical recommendations can be made. The ongoing RAPAMYCIN trial (NCT04488601) and other planned studies may provide the statistical power that PEARL lacked for definitive subgroup conclusions.

Frequently asked questions

›

References

Kraig E, Linehan LA, Liang H, et al. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance and cognitive effects. Aging Cell. 2024;23(4):e14024. PubMed
Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395. PubMed
Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6(268):268ra179. PubMed
Lamming DW, Ye L, Katajisto P, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science. 2012;335(6076):1638-1643. PubMed
FDA. Sirolimus (Rapamune) prescribing information. FDA Label
ClinicalTrials.gov. Rapamycin in healthy adults (NCT04488601). ClinicalTrials.gov